Abstract: Acyclovir, a widely used anti-viral drug, is the treatment of choice for initial episodes and management of recurrent episodes of genital herpes. Oral immediate release (IR) formulations of acyclovir have limitations of poor and variable bioavailability (15-30%), and dosing frequency up to five times a day. Such limitations lead to poor patient compliance and development of drug resistance. An oral extended release (ER) formulation of acyclovir can overcome these limitations. In the present study, a simple simulation technique for determination of the dose and in-vitro drug release profile required for an ER formulation of acyclovir to achieve steady state maximum and minimum plasma concentrations ( ss C max and C min ss ) similar to or better than those of an IR formulation, has been reported. First order drug release and absorption models were used. The dose and in-vitro drug release rate required for the ER formulation were found to be 725 mg and 0.259 h -1 , respectively. 
INTRODUCTION
For many years, oral route has been the most acceptable route of drug administration. This is due to many advantages such as convenience of administration, non-invasive nature and ability to accommodate numerous drugs. Different technologies and strategies have been developed to achieve desired in-vivo performance of drugs that widely vary in their physico-chemical and pharmacokinetic properties. An Extended Release (ER) / Controlled Release (CR) oral formulation is one such strategy that helps to achieve predetermined rate of drug release, leading to controlled plasma drug concentrations and subsequently to controlled therapeutic effect.
Acyclovir is a purine nucleoside analog with in-vitro activity against Herpes Simplex Virus (HSV), VaricellaZoster Virus (VZV), Epstein -Barr virus (EBV) and Cytomegalovirus (CMV) [1]. This drug has been shown to be of clinical benefit when administered topically, orally, or parenterally for the prophylaxis and treatment of certain herpes virus infections. It is recommended clinically for treatment of herpes zoster infections, genital herpes and chickenpox. Currently, acyclovir is one of the treatments of choice for initial episodes and management of recurrent episodes of genital herpes [2, 3] .
*Address correspondence to this author at the Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar, Punjab, 143 005, India; Tel: +91-9815899705; Fax: +91-183-2258819; E-mail: subheetjain@rediffmail.com In spite of its effective antiviral activity, acyclovir still has a number of biopharmaceutics and pharmacokinetic limitations like poor oral bioavailability of 15 to 30% with high variability and short elimination half-life of 2.3 h [4, 5] . These limitations necessitate frequent administration of acyclovir up to five times a day. This leads to poor patient compliance, which in turn leads to reduction in therapeutic efficacy and development of drug resistance. Acyclovir has a better solubility in low pH of the stomach and is predominantly absorbed from upper parts of the gastro intestinal tract (GIT). There are indications of its active absorption from the duodenum and jejunum regions of the GIT [6] . The fraction of dose absorbed from commercially available dosage forms is very low due to short residence time at the absorption site. As a result, most of the drug is excreted in faeces (5060%), in an unabsorbed form [7] . Hence, it can be envisaged that absorption and bioavailability of acyclovir can be increased by increasing residence time of the dosage form at the absorption site. A twice-a-day oral ER formulation of acyclovir will improve patient compliance and control fluctuations in plasma concentrations. The overall effect will be enhancement of therapeutic efficacy of this drug.
The first step towards successful development of an ER formulation of a drug is the determination of the required dose and release characteristics with due considerations to its biopharmaceutics and pharmacokinetic properties. In this work, an attempt has been made to determine the target dose and in-vitro drug release profile required for an ER formulation of acyclovir to achieve a pharmacokinetic profile similar to
